Future Perspectives in MSC–EV-Based Cell-Free Therapy

Nadiar Maratovich Mussin, Amin Tamadon

2026

Full text Open access: Hybrid Metadata (CSL-JSON)
DOI 10.1007/978-3-032-36437-1_12
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

This chapter explores future perspectives in MSC–EV-based cell-free therapy, focusing on precision medicine, bioengineering, and integration with artificial intelligence and omics technologies. It discusses emerging strategies for personalized therapy, advanced manufacturing, and clinical adoption. The chapter outlines a roadmap for transitioning MSC–EVs into programmable biologics, emphasizing the importance of standardization, potency definition, and regulatory alignment for future clinical success.